 |
1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide and ivacaftor |
|---|---|
| Trade Name | |
| Orphan Indication | Cystic fibrosis |
| EU Market Approval | EU |
| EU Designation Date | 2017-02-27 00:00:00 |
| Sponsor | Vertex Pharmaceuticals (Europe) Limited |
Related Access Program